CSN Login
Members Online: 14

You are here

Study suggests mCRC patients who take Bevacizumab beyond progresssion have significantly increased survival time

peterz54's picture
peterz54
Posts: 345
Joined: Feb 2012

I just read an article in press for Clinical Colorectal Cancer

Survival Outcomes of Bevacizumab Beyond
Progression in Metastatic Colorectal Cancer
Patients Treated in US Community Oncology - T. Cartwright

it indicates that mCRC patients who have completed their first line therapy and then take Bevacizumab (Avastin) during second line treatment (beyond progression) have a 6 month advantage in overall survival versus those that did not take Bevacizumab

this is consistent with information published in 2008 by Dr. Grothey

Subscribe to Comments for "Study suggests mCRC patients who take Bevacizumab beyond progresssion have significantly increased survival time"